Adolescent perspectives on adjunct-to-insulin therapies are important for understanding treatment acceptability in type 1 diabetes mellitus (T1DM). A qualitative analysis from the Adolescent Type 1 diabetes Treatment with SGLT2i for hyperglycEMia & hyPerfilTration (ATTEMPT) study, published in the Endocrine Practice, explored experiences with sodium-glucose cotransporter-2 inhibitors (SGLT2i) as adjunct therapy in this population.

The analysis included 24 adolescents aged 12 to 17 years (n=13 males). Using an embedded experimental mixed-method design, semi-structured interviews were conducted, and findings were evaluated using content and thematic analysis.

Three key themes emerged from the interviews. Decision-making about trial participation was described as multifactorial and involved both adolescents and caregivers. Adherence to adjunct SGLT2i therapy was reported as non-burdensome, without perceived disruption to daily diabetes management. Participation in the trial was also associated with greater awareness of ketone monitoring and improved self-management practices.

The findings indicate that adjunct-to-insulin therapy with SGLT2i was not reported as increasing treatment burden in adolescents with T1DM. These perspectives may inform trial design and research approaches in pediatric diabetes.